Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mass Automation Lowering Costs for ICANIC BRANDS (CSE: ICAN, OTC: ICNAF): https://oilandgas-investments.com/2020/latest-reports/mass-automation-lowering-costs-for-icanic-brands-ican-cse/
CloudMD (CSE:DOC, OTC:DOCRF) Increases Doctor Onboarding Amid Growing Coronavirus (COVID-19) Concerns https://finance.yahoo.com/news/cloudmd-increases-doctor-onboarding-amid-113010226.html?soc_src=hl-viewer&soc_trk=tw
“has increased doctor onboarding efforts for CloudMD, the Company’s direct-to-consumer telemedicine app, to handle the expected increased demand amidst the growing coronavirus spread.”
“Recent Media Coverage:
• https://vancouversun.com/news/local-news/what-if-a-pandemic-is-declared-in-canada
• https://omny.fm/shows/steele-drex/using-technology-to-combat-illness
• https://globalnews.ca/video/6614149/b-c-company-uses-simple-technology-to-help-manage-the-covid-19-outbreak
• https://ca.proactiveinvestors.com/companies/news/914509/cloudmd-has-built-solid-infrastructure-taking-telemedicine-to-whole-new-level-914509.html
• PRIVATE PLACEMENT UPDATE
The Company would like to announce, pursuant to its previously announced brokered financing with Gravitas Securities dated March 2, that the order book is through the base offering of $3 million based on significant interest, and the book will be closing Wednesday, March 11 at 4:00 PM EST.
Many are. I suggest you check updates here: https://ceo.ca/doc
CloudMD (CSE:DOC, OTC: OTCQB) has built solid infrastructure taking telemedicine to whole new level:
Great to see The Virtual Care Task Force (VCTF) pushing #virtualcare adoption forward across Canada: Task force outlines recommendations for virtual health care in Canada https://www.rcinet.ca/en/2020/02/11/task-force-outlines-recommendations-for-virtual-health-care-in-canada/ another validation for $PHGI $PHGRF @PremierHealthGI
Canada losing head start on 'virtual' health care: task force: https://www.kitchenertoday.com/around-ontario/canada-losing-head-start-on-virtual-health-care-task-force-2084287
Premier Health: A Valuation Comparison https://thedeepdive.ca/premier-health-valuation-comparison/
If you are feeling sick over the weekend & have to pick a way to see a doctor: Wait till Monday to go to a walk in Clinc and wait for a doctor 1-2 hours or see a doctor now via @PremierHealthGI’s CloudMD app https://t.co/xiPRYrUOTB. I know which one I would choose pic.twitter.com/Sx4VBcbBaM
— Makingmoneynow (@makingmoneynow1) February 8, 2020
https://thedeepdive.ca/ontario-opening-doors-to-video-based-telemedicine-and-digital-practices/
Premier Health Group (CSE: PHGI), wholly owns clinics, pharmacies and a SAAS based health technology solutions company that offers a cloud based EMR software. Currently their combined ecosystem covers over 315 clinics, over 3000 licensed practitioners and almost 3 million registered patients. The company recently announced the acquisition of LiveCare, one of the pioneering companies in Canada to offer encrypted face-to-face video and messaging to connect doctors to their patients. The other original telemedicine video conferencing player, Medeo, was acquired by QHR technologies, who was then acquired by Loblaws for $170M.
https://thedeepdive.ca/company-profile-premier-health-group/
Integrated Cannabis’ Ganja Gold is the Top Infused Pre-Roll Brand in California – with the #1 and #3 Best Selling SKUs
VANCOUVER, British Columbia, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Integrated Cannabis” or the “Company”), a multi-state brand operator in California and Nevada, is pleased to announce that its wholly-owned subsidiary, Ganja Gold, is the top infused pre-roll brand in California, through July 2019, with roughly USD$3,300,000 in sales to date for fiscal year 2019.
According to BDS Analytics, “This past July, consumers in California spent $25 million on Pre-Rolled products, a 66 percent increase compared to July 2018. While sales of Flower have ceded share to other categories, Pre-Rolled products are another matter. This past July, revenues from Pre-rolled products contributed nine percent towards overall revenue in California.” Furthermore, the number 1 and number 3 selling SKUs in the infused pre-roll category were Ganja Gold products - which are currently available in over 250 dispensaries all over California.
“The pre-roll and specifically pre-roll market has seen tremendous growth in the last year, and of late due to many factors, Seth Wiles, president of Integrated Cannabis. Wiles also went on to say, “We will leverage our standing as the best-selling infused pre-roll brand in the world’s largest cannabis market (California) to launch in other key states this Fall.”
http://www.globenewswire.com/news-release/2019/09/19/1917967/0/en/Integrated-Cannabis-Ganja-Gold-is-the-Top-Infused-Pre-Roll-Brand-in-California-with-the-1-and-3-Best-Selling-SKUs.html
https://finance.yahoo.com/news/premier-health-launches-proprietary-myhealthaccess-113000258.html?.tsrc=fin-srch
Premier Health Launches Proprietary MyHealthAccess App for Existing Patients on iTunes and Google Play
VANCOUVER, British Columbia, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it has launched its proprietary patient portal for its existing Juno Electronic Medical Records (EMR) patient database. The MyHealthAccess app is now available for download on iTunes and Google Play.
MyHealthAccess will enable patients in the Juno EMR database to directly interact with their healthcare providers and primary care clinics via a user friendly application. Through the app, patients will be able to book appointments in realtime 24/7, chat with clinical staff and see their doctor from the comfort of their home or office via telemedicine. The MyHealthAccess integration with Juno EMR, allows for an equally uncomplicated and user friendly experience for healthcare professionals and primary care physicians. Physicians will be able to access all appointments scheduled through the app directly in their EMR schedule in realtime, including telemedicine visits which can be initiated through a single-click with no need for different interfaces and crowded screens. MyHealthAccess will continue to evolve into a comprehensive patient portal that provides users a singular access point for all interactions with their healthcare providers and support staff.
Juno EMR, currently has a combined ecosystem of approximately 290 clinics, 3000 licensed practitioners and 3 million registered patients. The Company will soon be launching a direct to consumer app, that will offer doctor on demand services to patients not currently registered with Juno EMR.
“Technology is rapidly reshaping healthcare and we are excited to be at the forefront bringing convenient, patient-centric care to our existing Juno EMR userbase comprised of 3 million patients,” said Dr. Essam Hamza, CEO of Premier Health. “We further plan to roll out a telemedicine service, to both existing and new patients, across Canada which will ultimately be available 24/7. In the coming months, patients will also have the ability to access their charts & lab results, review & reorder prescriptions and share remote health monitoring data with their doctor – all at their fingertips. In addition, we plan to deploy aritificial intelligence (AI) to assist in triaging patients to the appropriate care ahead of their telemedicine appointment.”
Premier Health plans to provide an update on the roll out of additional features and adoptions rates in Q4-2019.
ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer
INTEGRATED CANNABIS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE CALIFORNIA CANNABIS MANUFACTURING BUSINESS
Further to its press release on May 27, 2019, Integrated Cannabis Company Inc. has entered into a share exchange agreement dated effective June 17, 2019, among the company, Ganja Gold Inc. (TargetCo) and the shareholders of TargetCo, pursuant to which the company will acquire all of the issued and outstanding shares of TargetCo. TargetCo is a California-based state and municipally licensed cannabis manufacturing business.
The acquisition of the manufacturing assets will allow Integrated Cannabis to directly participate in the California cannabis market in addition to further developing its X-Sprays products.
The proposed transaction
Pursuant to the terms of the definitive agreement, Integrated Cannabis will acquire all of the issued and outstanding securities of TargetCo in consideration for $12.4-million to be satisfied through the issuance of 40 million common shares of the company pro rata to shareholders of TargetCo at a deemed price of 31 cents per payment share upon closing of the proposed transaction. In addition, subject to the completion of certain milestones, the company may issue an additional 40 million payment shares pro rata to the former shareholders of TargetCo at a deemed price of 31 cents per payment share. The payment shares will be subject to a statutory hold period of four months and a day from the closing date as well as a voluntary hold period of 12 months from the closing date. The proposed transaction remains subject to certain closing conditions, including, without limitation: (a) the receipt by Integrated Cannabis of all necessary corporate and regulatory approval; and (b) each party's representations and warranties in the definitive agreement being true and correct in all aspects as of the closing date, and each party meeting its terms and conditions and completing its covenants and obligations as contained therein. There can be no guarantees that the proposed transaction will be completed as contemplated or at all. The proposed transaction is anticipated to close on July 5, 2019.
Subject to approval of the Canadian Securities Exchange, in connection with the proposed transaction, the company will issue 3.2 million common shares to an arm's-length third party finder at a deemed price of 31 cents per finder share. The finder shares will be subject to a statutory hold period of four months and a day from the closing date.
Both the CEO & CFO of Premier Health Group have been buying stock almost daily past few sessions, which is usually a great sign:
https://www.canadianinsider.com/node/7?menu_tickersearch=PHGI+%7C+Premier+Health+Group
Shorts on a Friday trying to shake shareholders. The bi-weekly shorts keep increasing and they need to cover see below:
Short Positions for PHGI
Symbol Report Date Volume Change Shares Issued % Float
C : PHGI 2019-02-28 271,868 115,838 61,164,031 0.44
C : PHGI 2019-02-15 156,030 -21,679 61,164,031 0.26
C : PHGI 2019-01-31 177,709 -90,521 61,164,031 0.29
C : PHGI 2019-01-15 268,230 48,210 61,164,031 0.44
C : PHGI 2018-12-31 220,020 -46,041 61,164,031 0.36
C : PHGI 2018-12-15 266,061 186,853 61,164,031 0.43
C : PHGI 2018-11-30 79,208 0 61,164,031 0.13
Executive Summary
EXECUTIVE SUMMARY
ParcelPal is the modern way for consumers to get products delivered from local businesses quickly and affordably. ParcelPal is the Uber of delivery by ways of a mobile application, an eCommerce integrated solution and a web-based service that lets consumers choose ParcelPal as a delivery method from local businesses and have it delivered in under an hour or less. Our technology handles the complete requirements of delivery logistics by bringing the merchants and customers onto a single platform.
The idea for starting ParcelPal Technology, Inc. originated in 2016. The company was founded in Vancouver, British Columbia and currently trades on the Canadian Securities Exchange under the symbol CSE:PKG (also on the Frankfurt Exchange: PT0 and the OTC Pink: PTNYF). Initially the company launched its B2B platform whereby merchants and users could log onto ParcelPal’s web portal and request a courier. This request was directly pushed to ParcelPal’s courier network and ‘accepted’ by one of the couriers through the courier application. The courier would proceed to fulfill the order and get the delivery completed within an hour or less.
To further their platform and open new market opportunities, ParcelPal has developed and currently is in process of launching their ‘Go Get It’ application. The focus of the application is a marketplace where consumers can order virtually anything in the city and have it delivered to them in an hour or less. The technology is available on iOS and is currently being developed on the Android operating system and as a web-based service.
While food delivery is not an innovative idea in itself, our business model addresses local logistics and delivery in an entirely new approach and methodology. ParcelPal’s vision is to make any local businesses inventory available and accessible to consumers within their city anytime, anywhere. ParcelPal services do not require a warehouse like traditional retail giants, which in essence competes with local businesses, rather ParcelPal gives local businesses the power of their logistics technology which in turn gives them the ability to reach a magnitude of customers.
ParcelPal has engaged local businesses with their software solution and plans to implement and expand further in the following key verticals:
Medical Marijuana (recreational pending legislation)
Alcohol
Food (quick service restaurants)
Retail goods
Get Anything (virtually anything!)
The biggest gain with on-demand delivery is that it blurs the difference in convenience between online and offline shopping. Customers are able to enjoy the flexibility and concessional pricing of online shopping and still have immediate product access that is native to offline shopping. On-Demand delivery is the next revolution in eCommerce that will reap in benefits for both retailers and merchants as well as their many customers. Combined with efficacy of ParcelPal, On-Demand delivery is a fuss-free affair for consumers and merchants.
We recognized one of the biggest problems people face is balancing work vs. personal life. Time constraints add to the stress we all experience. We've all found ourselves wishing we could spend more time doing the things we want to do, and less time doing the tasks we have to do.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.pkg&postid=28555413#c6bElHY8D2Tskqcp.99
Usefulness
Clarity
Credibility
Why you should buy Block One Capital now
10 reasons to buy Block One capital $BKPPF / $BLOK.V
1: Institutional investors loading up shares with big bids: https://twitter.com/makingmoneyn…/status/1025053597850128385
2: Finzat: Finzat continues to make strong progress as it develops relationships among key participants in the US whole loan market. Finzat has agreed in principle to terms with the leading provider of risk management software and a residential whole loan exchange for more than 120 existing financial institution clients. In addition, this firm has operating agreements with several US Housing Government Sponsored Enterprises (GSEs) and is in active dialogue with over 10,000 prospective participants for its whole loan exchange. A final agreement is anticipated with a formal announcement on or about the end of the 3rd quarter. Also, recent discussions with a GSE active in the ten trillion-dollar US residential mortgage market have served to highlight opportunities for a synergistic partnership whereby Finzat would bring benefits of blockchain applications to mature, well- established business lines. A formal proposal defining the terms of this relationship is being negotiated. Finally, Finzat is scheduled to open discussions before year-end with a European headquartered international financial management concern servicing hundreds of institutional clients around the globe. Among the firm’s activities are those that involve the assembly and dissemination of sensitive personal data, offering business potential for Finzat and blockchain technology.
3: Shopin: At the end of April, Shopin completed the final part of its Token, Generation Event. In total, Shopin raised gross proceeds of $42,500,000. Block One participated in the private presale portion of Shopin’s Token, Generation Event which concluded at the end of January. The timing and size of Block One’s participation precipitated a 66% token bonus to Block One.
Shopin recently announced a partnership with QRYPTOS, a subsidiary of QUOINE, one of the largest exchanges in Asia (and one of the few licensed exchanges in Japan). Shopin has announced that it believes this is an opportunity for it to expand awareness of its innovative work and community as well as its upcoming Q4 launch. Shopin also announced the additional sale of additional tokens at $0.16.
Block One believes its investment in Shopin reflects strong value creation for its shareholders as the original USD$750,000 participation with 66% bonus tokens is now valued at close to USD $2,000,00, reflecting a return of nearly
2.5 times its original investment.
Shopin was the Winner of Best ICO at the North American Bitcoin Conference and the Winner Best ICO at the CoinAgenda Bitcoin/Cryptocurrency investing conference.
Shopin, a private company is a pioneer in creating a blockchain solution where consumers own their own data. Shopin works with retailers to create a secure profile that enables shoppers to build and own their complete product preference and purchase data profile. Shopin unites retailers and their customers through personalized data intelligence for an unprecedented shopping experience within the participating retailers’ own sites, apps and stores and is expanding to publishing. Creating a more sustainable retail economy where retailers become stronger by working together with shoppers who get the most personalized experience and deals in every online and offline experience. Shoppers are rewarded by retailers through Shopin cryptocurrency based on the value of their data and for receiving ads, consuming and sharing content, engagement, and referring friends where they can spend the cryptocurrency along with FIAT (cash, credit cards) with the participating retailers.
Recently Forbes listed blockchain based identity and privacy as a leading breakthrough that will disrupt the tech and retail world in 2019, and identified Shopin in this space.
Furthermore, Shopin recently announced that it added aspects of its core propriety technology infrastructure to GitHub as part of a third-party audit commissioned by Quoine and performed by a representative of Novoa Media. The audit, though mostly internal, included aspects of Shopin’s artificial intelligence, personalization algorithms and back-end software for the purpose of showcasing the product development milestones Shopin is spearheading for the technology and crypto communities.
4: Affirmation Technology: http://www.stockhouse.com/…/block-one-capital-executes-defi…
5: Brokered private placement $2.000.000 at 1$
6: 8,900,000 shares in Haschain http://www.stockhouse.com/…/block-one-announces-sale-of-bit…
7: Great managment and advisary board https://www.blockonecap.com/ ( see presentation )
8: Buy before the smart money, 9 roadshows in near future with big investors waiting to buy https://twitter.com/EquityInsigh…/status/1023236662371995649
https://www.renmarkfinancial.com/comp…/block-one-capital-inc
9: Great financials: https://twitter.com/makingmoneyn…/status/1024157541578825728
Transaction was approved by the CSE and the symbol in Canada has been changed to ICAN on the CSE: http://thecse.com/en/listings/life-sciences/integrated-cannabis-company-inc
ICANNACO TO COMMENCE TRADING ON CANADIAN SECURITIES EXCHANGE
Integrated Cannabis Company Inc., doing business as iCannaCo, further to its press release of June 4, 2018, has now received final approval from the Canadian Securities Exchange, and the company's common shares will resume trading on the CSE on June 8, 2018, under the symbol ICAN.
New Directors and Officers
In connection with the closing of the acquisition, the Company announces that certain of its previous directors and officers have resigned. The Company announces that the board of directors now consists of John Knapp, Clive Spray, Sothi Thillairajah and Nishal Kumar. Management now consists of John Knapp (CEO), Clive Spray (Chief Scientific and Operations Officer) and Eugene Beukman (CFO and Corporate Secretary).
The following are brief descriptions of the new directors and officers of the Resulting Issuer:
John Knapp -CEO, and Director
A pioneer in the legal cannabis industry and trained engineer, John Knapp is the founder of Colorado-based Good Meds and Bosm Labs, both award-winning vertically integrated medicinal-grade cannabis business operating a 90,000 sf cultivation and extraction facility in Denver. Mr. Knapp is also the former COO of PharmaCielo, a Colombian based, globally focused medicinal-grade cannabis extract company.
Previously, Mr. Knapp's professional endeavors include highly specialized cannabis consultation. Among these tasks are the design and engineering of proprietary cannabis manufacturing systems enabling the optimization of production yield and manufactured product output. As an early entrepreneur in the legal cannabis sector and recognized expert in the field, Mr. Knapp has lead over two dozen cannabis projects in eight States, Canada and Latin America.
Clive Spray - Chief Scientific and Operations Officer and Director
Dr. Clive Spray has spent his career in plant biology and nutrition. In 2011, Dr. Spray co-founded Spray Labs LLC, with the express purpose of developing, manufacturing and marketing high-quality, efficacious nutritional supplements based on the previously developed spray delivery system. Over the last 6 years, Dr. Spray has continued to develop and enhance not only the delivery system but also the range of products. He received his undergraduate and Ph.D. degrees in Chemistry in the UK, during which time he published his thesis on the analgesic properties of plant derived natural products. His post-doctoral studies included 15 years of research at UCLA, working at the forefront of the mapping of plant genomes, and publishing 27 papers on the subject. Since 1997, Dr. Spray has been responsible for the development and production of a range of liquid spray vitamins and a number of powdered nutritional products and developed and innovative oral spray delivery system for nutritional supplements.
Sothi Thillairajah - Director
Mr. Thillairajah has two decades of experience in management, international finance, advising North American corporations on Middle East joint ventures and early-stage, mineral projects in Africa and Latin America. He also has extensive experience working with investment professionals at Middle Eastern financial institutions, sovereign-wealth funds, and investment offices evaluating and recommending hedge funds and private equity investments.
Nishal Kumar - Director
Mr. Kumar is an entrepreneur in Vancouver, British Columbia. Mr. Kumar worked at Geopacific Consultants Ltd., Tesla Motors, and now runs two of his own companies. The first one, EVitems, makes coat hooks and other after-market parts and products for the Tesla cars. With his other company, he recently launched a product called DHM Destroy Hungover Mornings - a plant-powered supplement that reduces hangover symptoms and the toxic effect of alcohol on your body. Nishal holds a BSc in Geophysics and Commerce from the University of British Columbia.
Eugene Beukman - Chief Financial Officer and Corporate Secretary
Mr. Beukman is Corporate Counsel of Pender Street Corporate Consulting Ltd., a private company that provides accounting, legal and administrative services, and has held this position since January 1994. Mr. Beukman was previously employed as a legal advisor to the predecessor of BHP Billiton, a leading global resources company, a producer of major commodities, including iron ore, metallurgical coal, copper and uranium, with substantial interests in conventional and unconventional oil and gas and energy coal, and a company that creates long - term shareholder value through the discovery, acquisition, development and marketing of these natural resources. Mr. Beukman has over 20 years' experience in the acquisition of assets and joint ventures.
Stock Options
In connection with the CSE listing, the Company also announces that 3,600,000 incentive stock options were granted to eligible directors, officers, employees and consultants of the Company in accordance with the Company's stock option plan (the Option Plan"). The options have an exercise price of $0.40 per share and are exercisable for a period of five years unless terminated pursuant to the terms of the Option Plan. The options and any shares issued upon exercise thereof will be subject to a hold period of four months and one day from the date of grant.
About the Company
Integrated Cannabis Company, Inc., d/b/a iCannaCo(TM), is a global wellness enterprise focused on the development, manufacturing, marketing and distribution of innovative and highly effective botanically-based consumable products.
Valuation of $IMTV is ridiculously cheap for a Company that actually generates decent revenue off of their events. They will make on average 300 to 500k an event and we are at the beginning of summer season where these events are just starting.
Can't believe that you can buy millions of shares sub 2 Million Dollar in Enterprise Value. This should be trading close to 10 Million without speculation.
Good luck to all longs,
Have a look at some of the following comparables and you can see how undervalued VNNYF is:
1) Life Style Delivery Systems (LDSYF), which has only one main product (Canna Strips) - following the recently announced $12M bought deal, they would be valued at c. 45Mcap
2) Radient Technologies (RDDTF) - an extraction company with an MoU with Aurora - valued at c. 100Mcap
With what VNNYF they have way more products coming and an extraction technology and more and is less than 20Mcap US.
Vinergy Resources/MJ BioPharma Announces Breakthrough in Oral Cannabinoid Strip and Time Release Capsule Technologies:
http://www.marketwired.com/press-release/vinergy-resources-mj-biopharma-announces-breakthrough-oral-cannabinoid-strip-time-release-cse-vin-2195699.htm
Vinergy Resources/MJ BioPharma to Acquire 65% of Health Canada and FDA Licensed Laboratory to Pursue Drug Testing and Dosage of CBDs, THC and Terpenes
http://www.marketwired.com/press-release/vinergy-resources-mj-biopharma-acquire-65-health-canada-fda-licensed-laboratory-pursue-cse-vin-2197634.htm
For investors looking for a growth stock that is disrupting a multi-billion-dollar market, market expert Michael Berger — President of Technical420 — highlights a Canadian-based development-stage healthcare technology company that is very undervalued and has remarkable growth potential.
Reliq Health Technologies (RHT: TSX Venture) (RQHTF: OTC) is a healthcare technology company that specializes in developing innovative, secure mobile software solutions for the multi-billion-dollar community care market.
Reliq offers a state-of-the-art iUGO Care platform, a comprehensive hardware and software solution that allows patients to receive high-quality care at home, which leads to improving health outcomes, a better quality of life for patients, and a lower cost of care.
The iUGO Care solution integrates wearables, sensors, a proprietary voice technology hub, and mobile apps and desktop interfaces for patients, clinicians and healthcare administrators. Reliq Health's proprietary iUGO Care hardware and software supports patients and their caregivers in the home, providing remote monitoring with alerts to clinicians as needed, audible reminders to improve patient compliance with prescribed medication regimens and lifestyle changes, tailored digital patient education materials and secure communication with the entire care team.
Investment Thesis
We are favorable on Reliq due to its ability to disrupt a multi-billion-dollar market, its strong management team that continues to execute on its initiatives, its four pilot programs, and its attractive valuation.
Piloting its Virtual Care Technology in the UK
In August 2016 Reliq announced that it had secured a pilot with the National Health Service in the UK. The pilot is focused on congestive heart failure and diabetes, two of the most common chronic conditions in the UK. Currently there are more than 15 million people in England that live with at least one long-term health condition.
Earlier this month, Reliq Health announced that it has started enrolling patients in the pilot of its remote patient monitoring and care collaboration solution with the NHS England. The goal of the pilot is to demonstrate the value of Reliq Health's self-care solution in improving health outcomes and reducing the cost of care delivery for chronic disease patients after they are discharged home from hospital. Imperial College Hospital, London, UK will serve as the clinical partner for this pilot.
The NHS England is the largest single-payer healthcare system in the world, with an annual budget of over £100 Billion. There are over 15 million patients in England who are coping with at least one long-term health condition. NHS England has estimated that improvements in self-care in this population could result in £584m in savings by 2021.
Executing on Two Pilots and a White-Label Contract in the United States
Reliq Health has announced two pilot programs in the United States. In one of these pilots, the company will be working with the interventional pain management clinic and surgical center at The Feldman Institute in Baton Rouge, Louisiana. The pilot will evaluate the use of Reliq Health’s technology with patients who have been discharged home after interventional pain management surgery, or have returned to their homes between treatments at The Feldman Institute.
The second pilot, which we are very excited about, is its program with Sacred Heart Health System in Florida. The Sacred Heart Health System is a healthcare network in Northern Florida consisting of three hospitals and Sacred Heart Medical Group, a large regional network of primary care and specialty physicians with offices across seven coastal counties. Sacred Heart is part of Ascension Health, the nation's largest system of Catholic and non-profit health care facilities.
The company has also secured a US$1.22M contract to provide professional services and a limited license to Reliq’s proprietary iUGO Care platform, specifically for the development of a consumer focused mobile health app (Mindful Health App) that will be provided by the City of San Antonio, TX to its residents to support them in proactively managing their own health.
Led by a Strong Management Team
Reliq Health is led by a strong management team with a proven track record of success before joining the company. Reliq’s CEO Lisa Crossley is an experienced healthcare IT executive and had previously served as the CEO of VitalHub Corp., Quantum Dental and Natrix Separations.
Giancarlo De Lio is the company’s Chief Visionary Officer. Giancarlo has a strong background in healthcare and information technology and a global network in the healthcare space. Giancarlo is a serial entrepreneur who previously founded and/or led successful businesses in the digital, mobility, healthcare and IT industries.
Reliq Health CFO Aman Thindal is a key component of Reliq’s team given his background in financial reporting, corporate structuring and tax management. He was previously the CFO of a mid-tier real estate development firm where he had been able to successfully raise capital.
Leo Godreault serves as the Vice President of Products and his background as a healthcare IT entrepreneur is a major benefit for Reliq. Prior to joining Reliq Health, Godreault founded SmartMED, a successful healthcare startup.
In late July, Reliq Health strengthened its Board of Directors through the addition of Brian Storseth. Prior to joining Reliq, Storseth was a Member of Parliament with the Conservative Party of Canada for 9 years from 2006 to 2015. During his tenure as an MP he served on committees for Aboriginal affairs, agriculture and agri-food.
Attractive Valuation
Reliq Health currently has a very small market capitalization, but with pilots in progress with multiple large hospital networks in North America and Europe, we feel it is poised for tremendous growth and associated increase in market cap. For this reason, we believe Reliq is significantly undervalued and underappreciated by Wall Street.
Reliq Health offers a very attractive opportunity for investors after it secured several pilot programs and this provides the market with a visible path for growth.
If Reliq is able to close at least one of the pilot programs, the company will be positioned for significant growth. Reliq currently has four pilot programs and this is very attractive since we expect to see them secure deals from at least two of these clients.
Tickers Mentioned: Tickers: RHT.V, RQHTF
http://www.moneyshow.com/articles/daytraders-45327/a-healthcare-disruptor-in-a-multi-billion-dollar-industry
Following is the cap structure (from slide 21 of the investor presentation):
Shares outstanding: 41.6M
Management & Insiders: 25.5M+ or 62%
Float: 15.5M shares of 38%
http://www.arcturusgrowthstar.com/wp-content/uploads/2016/02/AGS-Overview-2016.pdf
Hope this helps.
MMN
https://twitter.com/makingmoneynow1
This morning Arcturus Growthstar Technologies (CSE:AGS or US Pinks AGSTF) announced CBO Financial, Inc (http://cbofinancial.com/) as a Financial Partner & Advisor for with respect to New Market Tax Credits (NMTC) for a vertical Cannabis farm.
News key highlights:
1) The NMTC program is a $65 billion federal program designed to incentivize private investment in low-income communities;
2) The NMTC are provided to financial institutions in exchange for equity investments that eligible businesses can use to subsidize project development costs. The NMTC program would allow Arcturus an equity stake upto 25% in each of the selected farms in exchange of supporting low income communities through job creation..etc.
3) Arcturus’ partnership with CBO Financial is both shareholder and capital structure friendly in the sense that the draw of capital is non-dilutive in nature; and
4) CBO has secured over $500 million in NMTCs for clients;
5) This is the first of many projects that Arcturus & CBO plan to work together on.
Link to news can be found here: http://www.prnewswire.com/news-releases/arcturus-announces-engagement-of-financial-advisor-for-vertical-farm-project-595243311.html
Mike is the Ex-Chairman and a current shareholder based on SEDI.
Uplisting from Pinks to OTCQB would make sense and I suspect that is why they announced the hiring of the prestigious Boutique I-Bank out of NY.
Time will tell, but given the float and how hot the space is, we could see some good traction so long as management executes.
Arcturus Growthstar Technologies Inc
AGS.C / AGSTF
Current market cap of 1.6M
Float less than 10 million shares
AGS is in advanced discussions with 4 Targeted Produce Farms in the Eastern US
***** Each license deal is >$3M
3 of the 4 are New Market Tax Credit (Federal Government Program) Projects in Partnership with a strategic financial partner
Share structure:
· 35M shares outstanding, 66% owned by management with voluntary escrow clause.
· Float of less than 13M shares, 3M of which were from the original shell with average cost of 1$
· Current market cap (September 2, 2016) of 1.6M Canadian
Upcoming milestones:
· Development of an exclusive Equipment Lease Program throughout the U.S.
· JV with a Medicinal Permitted Grower/Distributor
· JV Production Venture in Canada
· JV Licensed Production Ventures in US
· Up-list to the US OTQB
· Accretive Acquisitions
· Commercialize LED technology to several Cannabis farms
· Become cashflow positive in Q1-17
“One single vert farm approved and operating triples the current value of the entire company.
Jesus Christ on a pogo stick, you have to love it when a company comes along that just drips undervalued.” http://www.equity.guru/2016/08/24/arcturus-growthstar-technologies-ags-c-ceo-explains-cannabis-aeroponics-potential/
The Company has 3 divisions under its umbrella:
1) Cultivation – AGT plans to be one of the leading companies in vertical farming using its proprietary Controlled Environment Agriculture (CEA). Arcturus provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds a worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. AGT already announced the lease for its first flagship farm in Rohde Island, which will become operational and revenue generating in Q4-16 with focus on Cannabis produce.
http://www.thenewswire.com/archives?tnwcatalyst2=release_id%3D19917
2) LED Division – AGT also in the business of developing and distributing LED based lighting solutions for both commercial and residential applications and is focused specifically towards Cannabis. The Company’s Growthstar brand of LED lights have been top rated for almost 5 years and its newest COB and MCOB (Chip on Board and Multiple Chips on Board) technologies are proving to be game changers in the world of “LED Grow Lights” with 50% reduction in power use and many other benefits. AGT’s Scorpion Grow Lights already won 1st Place Award at Cannabis Cup allowing growth of plants grown legally using an MMAR patient license - See more at: http://www.thenewswire.com/archives?tnwcatalyst2=release_id%3D19950#sthash.nIYlC3Xr.vOw6SJj9.dpuf
3) Agri-Tech – AGT is currently in negotiations to acquire or JV with revenue producing Agri-Tech businesses that are already cashflow positive with huge potential of growth.
Management:
Ø Bill Gildea, MBA, CEO, Director - is the founder and president of ECAP LLC, a boutique investment firm. With over 20 years of experience, he is recognized as a pioneer in the field of environmental insurance, and has a strong record of successfully advancing environmental businesses and projects through effective finance and investment Strategies including uplisting one of his prior ventures on the NASDAQ as well as 2 other successful exists.
Ø John Sweeney, Director & COO - Mr. Sweeney brings with him 16 years of direct cGMP (current Good Manufacturing Practices) manufacturing experience in operations of industry leading biotechnology companies including Pfizer, Wyeth, Genzyme and most recently as Vice President of Operations at Tilray, a 60,000 square foot federally licensed Canadian medical cannabis operation on Vancouver Island. He has extensive knowledge and experience in the requirements of regulated manufacturing for commercial and clinical products and served as liaison for auditing regulatory agencies including the FDA and EMA.
Moseda Technologies, Inc. (MSD.V of FLNTF) updated executive summary
www.moseda.com
Connected care. Everywhere.
Elevator Pitch
Moseda Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market. Moseda’s powerful CareKit Health platform supports care coordination and community-based healthcare. The CareKit platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. CareKit Health allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. Our platform provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.
Problem
As the population ages, global healthcare costs are rising significantly and the existing healthcare business model is rapidly becoming unsustainable. Demand by governments, HMO’s and patients for more efficient healthcare is driving healthcare organizations to reduce costs by moving care out of the acute, inpatient setting into the community. The key challenges in the community setting include:
• Poor access to specialized care in remote, rural and inner city settings
• Shrinking percentage of healthcare personnel to care for more complex continuing care patients
• Chronic diseases account for 79% of all U.S. healthcare spending, but chronic conditions are often poorly managed by patients at home leading to complications and the need for hospitalizations, long term care facility admissions and other costly interventions
Solution
The CareKit Health platform provides remote patient monitoring as well as secure communication between providers, patients and their families. In the patient’s home, CareKit uses wearables to collect patient health data and sensor technology to provide contextual reminders and to help visually or cognitively impaired patients with wayfinding. Our interactive voice technology provides patients with audible alerts and reminders, along with voice-activated access to all of the information available through CareKit including patient education materials, care team contact information, a summary of previously-collected patient health data and a current schedule of home visits, virtual consults, doctor’s appointments and other upcoming interventions. CareKit Health empowers patients to actively participate in managing their own health at home. Our platform was designed specifically for chronically ill and elderly patients, as well as homecare providers and family members who may not be particularly tech-savvy. CareKit Health also provides a robust administrative dashboard to facilitate patient population and care team resource management.
Market Opportunity
The global market for Community-Based Care or Virtual Healthcare (Telehealth) reached $19.2 Billion globally in 2014 and is expected to grow at a CAGR of 17.7%, exceeding $43 Billion by 2019 (BCC Research, Sept. 2014).
Competitive Advantage
Moseda offers the only comprehensive solution for patients, families, care team members and healthcare administrators. The CareKit platform leverages our proprietary sensors and voice technology hub to make our product truly user friendly for all patients. Moseda is also unique in our ability to integrate with EMRs or other clinical information systems, which supports the complete continuum of care from the acute setting to community physician practices to the home.
Revenue Model
Moseda offers two pricing structures:
1. Upfront software licensing fee with annual support & maintenance fees
2. Monthly subscription fees per user
Moseda expects to achieve revenues of >$3M in 2016, growing to over $50 Million annually by 2019.
Commencing Q2-2016
Moseda launched the CareKit Health platform in February 2016 and has already secured contracts in the US, UK and Canada.
Contact:
Lisa Crossley, CEO
(888) 405-9549
crossley@moseda.com
lcrossley@carekithealth.com
www.moseda.com
www.carekithealth.com
Management Team:
Lisa Crossley, CEO
Lisa is an experienced healthcare technology executive with deep domain knowledge. Prior to joining the Moseda team Lisa was the CEO of VitalHub Corp., CEO at Quantum Dental Technologies and President & CEO at Natrix Separations. Lisa has raised >$35M in venture capital and angel financing in the US and Canada & built customer bases in North America, Europe & Asia. She has a BSc in Anatomy & Cell Biology from McGill University and a B.Eng. and PhD in Chemical Engineering from Queen’s University.
Aman Thindal, CFO
Aman was previously the CFO of a mid-tier real estate development company. He has secured >$75M in financing and has extensive experience in financial reporting, corporate structuring
and tax management strategies. He also has significant expertise in joint venture structuring. Aman is a CPA and CA and has a BBA from Simon Fraser University.
Giancarlo De Lio, Chief Visionary Officer
Giancarlo has previously founded numerous successful businesses in the marketing, digital, healthcare and IT markets including his most recent success, VitalHub Corp., which developed a mobile charting application for the enterprise mHealth market. Prior to VitalHub Giancarlo worked at Mount Sinai Hospital in Toronto, developing innovative IT solutions for the clinical teams. Giancarlo has a BSc in Computer Science from the University of Toronto and an MBA from U of T’s Rotman School of Management.
Leo Godreault, VP Products
Leo is a Registered Nurse who specializes in Clinical Informatics. Leo has previously founded two healthcare IT companies designed to improve the patient and clinician experience, ShiftAlerts and SmartMED. Leo brings a unique combination of IT expertise and clinical experience to the CareKit Health team. Leo holds a BScN from McMaster University and Mohawk College.
Check out Q4 results for Moseda (MSD.V or FLNTF) at: http://sedar.com/Displ...
Key highlights:
- Revenue grew from c. 9k Q414 to 338k in Q415
- The Company recorded a gross margin of c. 42% during Q4
- Loss for the quarter 477k
- Strong balance sheet position with 808k in cash, 263k in receivables, 258k in prepaid expenses and 23.5k in inventory
- Payables reduced to 215k
The Company has enough cash for the rest of 2016 and that will likely extend further as more revenue is realized.
MMN
https://twitter.com/makingmoneynow1
Summary of Carekit
The CareKit Health platform acquired by Moseda enables complex patients to receive high quality care at home through the use of innovative technology, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.
Moseda's proprietary technology offers the only solution available today that comprehensively addresses the needs of complex continuing care (e.g. CHF, COPD, Diabetes, Palliative Care, Post-Surgical) patients, their families AND the entire care team. Moseda's technology provides ALL of the members of the circle of care with access to the patient's medical record, care plan and timeline (listing past and future home visits, virtual consults, physical appointments, procedures, etc.). The Moseda platform supports secure communication between all members of the care team as well as with the patient and family. This promotes collaboration amongst care team members, reduces the risk of redundant tests, procedures and home visits, helps ensure high quality care in the home environment with the corresponding low cost of care delivery, and increases patient and family satisfaction by keeping them in the loop.
In the home, Moseda uses unique iBeacon technology to provide unique contextual alerts, reminding patients to perform tasks assigned by their care team whenever they are near the relevant equipment (e.g. weigh themselves when they are near their scale). The iBeacon technology also supports wayfinding to help visually impaired patients navigate their home, and can be used to help informal caregivers locate key equipment (e.g. medication dispenser, oxygen tanks, TENS units, etc.). The platform can be used to deliver educational videos or reading materials to help inform patients and family members. The platform also provides task lists that are created by the care team to help direct the patient in self-care and guide informal caregivers (family, friends) to help them support the patient's care in the home environment. The Moseda system was specifically designed to be highly intuitive and user-friendly to allow ill/elderly patients and their caregivers who are not technically savvy to learn and use the system with ease.
The current model for caring for complex patients with chronic conditions is to monitor them post-discharge for risk of readmission and death using in-home care providers where available, family or other informal caregivers, the patients themselves, primary care providers and specialized outpatient clinics (e.g. CHF, COPD, diabetes clinics) where they exist. This approach does not provide a consistent experience for all patients, is not cost-effective, will be impossible to scale as the population ages, and as clearly illustrated in the literature is not effective at reducing complications, ER visits or readmissions.
With the acquisition of CareKit, Moseda now offers a uniquely comprehensive solution for patients, families, care team members and healthcare administrators, and leveraging proprietary sensors and voice technology to make the platform truly user friendly for all patients. Moseda is also unique in its ability to integrate with EMRs or other clinical information systems, which supports the complete continuum of care from the acute setting to community physician practices to the home.
Our platform, unlike competitive remote patient monitoring products, was designed to provide the intuitive, user-friendly experience of a typical consumer-focused product, while also providing the robustness, reliability, security and privacy (HIPAA/FOIPPA compliant) required for enterprise solutions in healthcare. Our product uniquely addresses the needs of all of the stakeholders in the circle of care, from patients to loved ones to clinicians to healthcare administrators
MMN
https://twitter.com/makingmoneynow1
Greetings all,
Please find below the link to a follow-up interview with Lisa Crossley explaining the acquisition of Carekit and what it adds to Moseda. Key highlights to what should be forthcoming:
* The Company will be cash flow positive by year end
* CEO would be disappointed if revenues are less than 3 million
* Recurring revenue
* Significant strategic partnerships
IPO and Turnaround
The Company went public as an RTO earlier this year at 20 cents (valuation of c.8.4M Canadian) and did not fair well. At that point, the company started with a focus on Logistics and as the market was not as large and market penetration was slow, interest in the stock started to fade away, resulting in a SP as low as 8 cents.
The company shifted its attention and focused on the Healthcare Industry. Since than the SP hit a recent high of 36 cents and MSD has been achieving revenue generating milestones at a very fast pace.
In my opinion, Moseda’s current management has demonstrated great business intelligence and agility in this switch of focus. While Moseda’s is currently very much focused on the healthcare industry, this does not diminish any of the milestones reached in the Logistics industry. In fact, Moseda continues to maximize the value of such assets through the pursuit of potential partnerships and/or acquisitions.
Business
In short, the company is in the business of Mobile Device Management and Browser Security. Essentially, Moseda has created a mobile device tracking platform with state of the art security features attached. While the technology can be used in many industries, Moseda supports applications in the oil & gas, Logistics, and Healthcare industries.
Competition
Whilst it's tough to pin down direct competitors to Moseda, the closest competition is Patient Home Monitoring (PHM.V). However, Moseda is more of a complimentary to what Patient Home Monitoring does. Essentially, MSD would perfectly compliment a company like PHM with their technology.
Balance Sheet
Company has close to 1.3M in cash aside from proceeds from the 2 recent purchase orders (350k + 250k). Last raise was done a few months back at 20 cents.
Monthly burn rate is between 60 and 70 thousand dollars. The Company has a run rate to Q1 2017. No need to go back to the market any time soon, unless the company fins an attractive acquisition that would have a positive impact on revenues and the SP.
Share Structure
Current float is 52M shares, with 9M locked in a placement split into 2 tranches that comes free late January and early February. The CEO and his family own close to 20% of the float and our network including us own c. 40% of the float.
There are 7.5M warrants that are at 35 cents and are open for another 14 months.
Following, I will focus on the Healthcare industry applications or ‘Smart Health Solutions’.
Main Line of Business: Smart Health Solutions
Anyone that has recently visited a hospital in Canada knows that there is a clear mandate to eliminate all paper records and to make the move to maintaining all patient records digitally. Additionally, digitizing patient records comes with a need for increased efficiency and automation of many tasks performed in the healthcare industry.
The company is essentially taking the old healthcare model of managing tasks manually and recording patient's data (tests, vital signs, etc.) using pen and paper to a an automated model that allows data to be placed on a mobile device in a secure manner through data encryption. The data is stored on the cloud and is only accessed by authorized personal. This in turn allows hospitals or other patient care facilities to reduce hours spent by healthcare practitioners performing their daily tasks, leading to increased staff productivity and significant cost savings. The model will be expanded further over the next few months to key segments such as home care patients.
In summary, amongst many other applications, Moseda’s software does the following: a) improves the efficiency of healthcare professionals by managing their tasks and providing them with necessary reminders and alerts, b) communicates directly with wireless medical devises with no manual intervention (thus eliminating potential human error in reading the information or manually transferring the readings from paper), and c) maintains all this data on the cloud in a secure manner.
To read more, please check the Company's link below: https://moseda.com/smartcare
Applications of Moseda’s software in the Healthcare industry
Mobile Application
Secure digital patient record keeping
Access to records from anywhere
Comprehensive analytical health charts
Send, receive, and store files securely
Digital Health Records
Review historic patient health record
Record notes on patient health performance
Collect assessment tests from patients
Monitor patient data charts and diagrams
Task Management
Schedule and assign tasks
Monitor patient health status in real-time
Send & receive patient notifications and alerts
Capture patient data digitally on-the-go
Connected Wearables
Instant readings from wearable devices
Measure blood pressure, blood oxygen, blood sugar, body weight, bone mass, etc.?
Automatic data upload to patient records (no manual data input required)?
Revenue Drivers
Monthly Subsription/ $10 - $20 per month per patient
Standard SmartCare software license to manage patient health performance in long-term and home care environments
Video Consultation/ 10% of consultation fee*
Custom SmartCare video platform to facilitate remote doctor - patient consultations?
* average 20 minute doctor consultation fee = $50
Hardware / 40%+ profit margin**
SmartCare - approved hardware incl. smartphones, tablets, blood pressure monitor, weigh scale, wristband, oximeter, among others
** prices range between $50 - $1,200 CAD
Other (see below) / Blue Sky potential
While devise sales will generate the largest initial revenue, the monthly subscription will provide recurring cash flows on a medium and long-term basis.
Another revenue stream that will be very valuable when Moseda hits the 20-25k patient mark is the sale of patient statistics and data (aggregated information with no personal information attached) to interested parties such as insurance companies, pharmaceuticals, and HMOs. Essentially, think of any insurance Company in the world, they all need such data to do their actuarial analysis to determine insurance premiums. This type of information is very valuable to many companies and has no cost attached (100% profit margin). This in my opinion is where the blue sky is.
Why Invest Now
Recent achievements and milestones not fully priced into current SP
Pivoted to focus on Health Care applications for home and institutional patient monitoring.
Received a Medical Device Establishment License from Health Canada in September
Negotiated a deal w/ an international Top 5 Pharmaceutical and Medical Device company to become an distributor of their products
Executed on a $350,000 sale (40% margin) to a customer servicing over +50,000 patients in the home care space
Received a second purchase order for $250,000 sale (40% margin) from the same customer within 1 month of the first order
Launched a pilot project with a multi-location client in western Canada. Moseda is implementing its mHealth technology to help the client manage digital health records, monitor patient daily vital signs, track patient visits and organize personnel.
More revenue generating contracts and partnership expected early 2016
Moseda is on the cusp of securing more key contracts with healthcare providers in Canada and the US. We also think that with the growth of home patients and home care in NA, the subscription revenue stream, could be a substantial driver to both revenue and valuation.
No regulatory hurdles involved (Health Canada License to import and sell devices obtained) With this license, MSD can sell its software to be added to customers’ existing devices or sell them the medical devices they need with the software installed. With this step, MSD becomes a one stop shop and gains full access to the market, devices + software + additional add on services.
Low burn rate
MSD uses highly skilled contractors as needed, thus keeping their cost very low. Also, MSDs CEO has a tremendous amount of connections worldwide in the healthcare and home patient care industry. He has been the key to signing up the recently announced (unidentified) customer
Insiders have skin in the game and CEO wants to create a legacy with MSD
Insiders own a ton of shares, from my last account around a month ago the CEO owns approximately 3.3M shares, and along with a few close family and friends a total number of shares held of approximately 5.8M.
Also, the CEO is dedicated to the company 24/7 and is constantly expanding the product offering and capabilities based on discussions with potential customers and industry leaders. His background is mainly in mobile security, which will be the main differentiator and key success factor for Moseda in an industry that puts tremendous value on patient confidentially and information security.
No need for market financings
MSD has recently been cashed up with a 1.5 million infusion in addition to the profit made on the 350k initial order. With a 720k annual burn rate, MSD has a run rate until approximately Q1 2017, not considering current and potential revenues.
What’s to come?
Recurring revenue potential is near terms w/ our home care client
Additional revenue from pilots turning definitive – expected in January
Diversity of revenue (ie: multiple sources)
Q: What will take MSD to new highs?
Macro: The baby boomers market is growing; 10,000 people turn 65 every day in the US; moving to an assisted living facility is an absolute last resort for most people; they want to remain independent; doctors/nurses/practioners are economically incentivised by payors to utilize technology in the delivery of care.
Micro: MSD has very strong relationships with its’ current customers and is talks with many potential new customers – they are industry leaders (with security as main differentiator) and carry a strong degree of clout that will open up doors for additional revenue generation. A ramp up of revenue is underway and I expect that a large portion of it to be recurring revenue. Moseda is being approached on a weekly basis by organizations such as long term care homes that want to adopt or pilot their technology.
Hear interview with CEO below:
http://www.midasletter.com/2015/12/moseda-technologies-ceo-nick-murray-aims-for-billion-dollar-market/
MMN
https://twitter.com/makingmoneynow1
Moseda Technologies still remains under the radar to date. Despite the many significant milestones achieved to date including:
1) Moseda changed its focus towards the Healthcare vertical in July 2015
2) Board was changed with additions including Sameet Kanade, who is the Head of IT Investment Banking at Jacobs Securities. In addition to a capital market savvy CFO, who is the brother of one of the partners that truly moved this deal.
3) Improved balance sheet by adding an extra 1.5M in an equity raise
4) Received Health Canada Approval for Medical Device Establishment License
5) Was selected by a top 10 Pharma in the world to be a distributor in Canada
6) Locked its first significant revenue of $350,000 from a Home Care Company that has over 20,000 patients
7) Locked its first pilot service agreement with a multi facility Home Care Health Company in Western Canada
8) Secured a second purchase order for $250,000 from a Home Care Company with over 50,000 patients
9) Formed a major partnership with an international Beacons providers that allows for tracking of Home Care facilities assets.
However, I believe we are at the cusp of getting the word out in the New Year and the few quarters to follow.
Some of the recent 2016 trends suggest that technology followed by healthcare are the 2 hot sectors where HNWI are placing their capital:
Psilos VC: Digital Health Will Emerge as Top Performer in 2016: http://www.xconomy.com/new-york/2015/12/21/psilos-vc-digital-health-will-emerge-
as-top-performer-in-2016/
States Take the Lead in Paying for mHealth: http://mhealthintelligence.com/news/states-take-the-lead-in-paying-for-mhealth#.
VnmNOqzsaRE.twitter
This is one of our 2 major holdings where our investment horizon is 6 to 12 months and maybe more. Clearly that does not suggest lack of diligence during that timeline.
Merry Christmas & Happy New Year
MMN
https://twitter.com/makingmoneynow1
VANCOUVER, March 5, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.
"We are pleased to have completed follow up on the last patient reaching the eight month visit on schedule," said Andrew Rae, President & CEO of iCo Therapeutics. "This achievement is largely due to the tremendous support and commitment we have received from our study Chair, participating clinical sites and our partner JDRF. We currently expect to announce top-line primary endpoint data before the end of April and secondary endpoint data before the end of the third quarter."
iDEAL Trial Design
The iDEAL trial explores whether varying combinations and concentrations of iCo-007 are effective in improving visual acuity in people with DME--the leading cause of functional vision loss among working Americans, in which leakage of fluid from blood vessels in the eye causes the retina to swell, leading to blurred vision and blindness. The Phase 2 clinical trial is a multi-center study, with recruitment at 28 clinical sites across the United States.
The study follows patients for a 12 month period. During the trial, patients were randomized into one of the following four groups:
-- Mono-therapy using repeated intravitreal dosing of iCo-007 at 350 ug, at
day one and month four.
-- Mono-therapy using repeated intravitreal dosing of iCo-007 at 700 ug, at
day one and month four.
-- Combination therapy using repeated intravitreal dosing of iCo-007 at 350
ug with laser photocoagulation. iCo-007 at day one followed seven days
later by laser photocoagulation, then iCo-007 at month four and if the
eye meets retreatment criteria, it will also receive the second laser
photocoagulation seven days later.
-- Combination therapy using repeated intravitreal dosing of iCo-007 at
350ug with ranibizumab (Lucentis(R)) at 0.5 mg. Lucentis(R) at day one,
iCo-007 at two weeks, then Lucentis(R) at month four and iCo-007 two
weeks following.
Some patients may be eligible for a third dose at month 8 based on a retinal thickness measurement and evaluation by the clinical investigator.
To be eligible for the trial, participants must have type 1 or type 2 diabetes, baseline best corrected visual acuity between 20/32 and 20/320 and DME with central retinal thickness equal to or greater than 250 microns measured by optical coherence tomography (OCT).
This is an investigator-sponsored study and there is some reliance on the Coordinating Center and Study Chair to continue to meet stated goals for timing of data delivery.
For information about this study, please visit www.clinicaltrials.gov.
About Diabetic Macular Edema (DME)
DME occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. These leaks cause the macula to thicken and swell, progressively distorting acute vision. While the swelling may not lead to blindness, the effect can cause a severe loss in central vision. DME is the major cause of vision loss in people with diabetic retinopathy. People with diabetes have a 10 percent risk of developing the condition during their lifetime. It is estimated that close to 1,000,000 people in the United States have DME.
About iCo-007
A second-generation antisense inhibitor targeting C-raf kinase may prevent the signaling of multiple growth factors, which in turn prevent the production of new and permeable blood vessels in the back of the eye. Recent publications have shown that the pathways activated by Ras/Raf may play a crucial role in diabetes-associated complications including diabetic retinopathy. Due to its mechanism of action iCo-007 may eventually be applicable to neovascular form of age-related macular degeneration (AMD) and other ocular indications, as well as DME.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will," and similar references to future periods and includes, but is not limited to, statements about the intended use of proceeds of the Offering. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.
/CONTACT: Mr. John Meekison, CFO
iCo Therapeutics
604-602-9414 x 224
meekison@icotherapeutics.com Michael Moore, Investor Relations
TMX Equicom
858-886-7813
mmoore@tmxequicom.com
Copyright CNW Group 2014
ICOTF gets a new coverage by Zach small Cap resreach
Zachs small cap research just issued coverage on ICo Therapeutics with an initial target of 90 cents, which is on the down side. Zach places iCo valuation at 100 to 150 million dollar based on a 50% success rate for 007. This translates to a range between 90 and a 1.30 assuming all warrants are exercised (see link below).
This further shows how undervalued iCo is currently and the big win will be if 007 primary efficacy data comes positive, which would lift the 50% odd and make the Company worth anywhere between 1.80 and 2.60.
So between now and data, we have more than a double on the table to be taken. That is a potential 100% to 150% within only 5 to 9 weeks away!!
I believe yesterday's volume of 2.2m along with the price appreciation of 13% is just the start of a major run towards data.
Good luck with your investments,
MMN
http://scr.zacks.com/files/doc_coverage/Biotech%20-%20Jason%20Napodano/ICOTF/Feb
ruary%2025%202014_ICOTF_Napodano.pdf
https://twitter.com/makingmoneynow1
ICOTF doing quite well on the Canadian side. Already traded 330k and is up by 12%.
Management are being tight lipped, but seems the spec run is starting.
MMN
The last PP on $ICOTF was all funds, the guys at AMW controls 16.7%, ISIS 8% and insiders own 9% aside from 2 other US funds that did not report (10 million shares), so all in all, they have more than 40% locked.
I believe the big win for ICOTF is if combined with Lucentis they can reduce injections, which one of the arms of this trials is covering.
We shall see.
MMN
The clinicians obviously know which trial arm a patient is in, but with 28 active clinical sites and patients spread amongst those sites, no one clinician has enough patients to understand efficacy. The company itself is also fully blinded, so we have no idea as to how it’s going at this time.
Their is an arm to the trial with Lucentis and I believe the idea of Ph2 is to prove that the combined drug would have the same results as iCo with less frequent injections.
BTW, ICo owns 6% of IMNP (trading on Nasdaq) at 50 million mcap and they outlicensed a drug from iCo.
Feel free to contact the Company's IR for any more specific questions.
Michael Moore
Vice President, United States
TMX Equicom, Investor Relations
T: (858) 886-7813
C: (619) 302-4431
mmoore@tmxequicom.com
Hi Biocqr,
I am not sure how much you know about $ICOTF or ICo Therapeutics, but I can tell you that I have known this Co for 5 years and have been in and out twice before finally putting lots of dollars almost 18 months ago.
The problem that iCo has had was that it is one of the largest US based trials done by a Company that does not trade there. The Company has changed that last December by getting listed on the US QX exchange, but still pending DTC.
The idea of being a Canadian biotech and trying to get a Vancouver crowd to give proper valuation has proven to be weak and hence the migration to the US side. The Company started a run earlier this year, which was stalled by a financing that gives the Company enough cash to run to Q4 2015. The funding came through 3 US based funds and it was done through HC Wainright.
http://www.hcwainwright.com/
If you check HC's transactions, you will see that they only take high profile mandates.
If you look at what they have to with Rexhan or IGX tech our of Canada you can see how powerful they can be.
See below who bought in that latest financing and that may give you more comfort.
Happy to discuss more.
MMN
Class of securities reported upon Part 4 of National Instrument 62-103 The Early
Warning System and Related Take-Over Bid and Insider Reporting Issues:
Common Shares (“Shares”) of iCo Therapeutics Inc. (“iCo”).
(a) Name and address of the eligible institutional investor:
AWM Investment Company, Inc. (“AWM”)
527 Madison Avenue, Suite 2600
New York, New York 10022
(b) Net increase or decrease in the number or principal amount of securities,
and in the eligible institutional investor’s securityholding percentage in
the class of securities, since the last report filed by the eligible institutional
investor under Part 4 or the early warning requirements:
This is the initial report filed by AWM under Part 4 of NI 62-103. AWM
serves as investment advisor to Special Situations Fund III QP, L.P. and
Special Situations Life Sciences Fund, L.P. (the “Funds”). The Funds,
identified in paragraph (c) below, each advised by AWM, collectively
purchased 5,402,161 Shares and warrants to purchase 4,051,621 Shares, in an
offering that closed on January 27, 2014.
(c) The designation and number or principal amount of securities and the
eligible institutional investor’s securityholding percentage in the class of
securities at the end of the month for which the report is made:
10,487,161 Shares and warrants to purchase 4,051,621 Shares of iCo are held
by two funds (the “Funds”), which are advised by AWM, representing
approximately 16.5% of the issued and outstanding Shares as of January 27,
2014 following the completion of the offering and assuming the exercise in
full of all warrants held by the Funds.
Special Situations Fund III QP, L.P. owns 5,243,817 Shares and warrants to
purchase 2,025,811 Shares or approximately 8.4% of the Shares outstanding
assuming the exercise in full of all warrants held by it. Special Situations
Life Sciences Fund, L.P. owns 5,243,344 Shares and warrants to purchase
2,025,810 Shares or approximately 8.4% of the Shares outstanding assuming
the exercise in full of all warrants held by it.
(d) The designation and number or principal amount of securities and the
percentage of outstanding securities referred to in paragraph (c) over which
(i) the eligible institutional investor, either alone or together with any joint
actors, has ownership and control: 5610068 v1
- 2 -
The Funds own the Securities in question as indicated in paragraph (c) above,
and AWM controls such Securities, as investment advisor to the Funds.
(ii) the eligible institutional investor, either alone or together with any joint
actors, has ownership but control is held by other entities other than the
eligible institutional investor or any joint actor:
The Funds own the Shares in question as indicate in paragraph (c) above.
(iii) the eligible institutional investor, either alone or together with any joint
actors, has exclusive or shared control but does not have ownership:
The Securities of iCo as indicated in paragraph (c) above are controlled by
AWM, as investment advisor to the Funds.
(e) The purpose of the eligible institutional investor and any joint actors in
acquiring or disposing of ownership of, or control over, the securities,
including any future intention to acquire ownership of, or control over,
additional securities of the reporting issuer
AWM controls the Securities of iCo on behalf of the Funds for investment
purposes. AWM and/or the Funds may purchase additional Shares and/or
other securities, or dispose of Shares, and/or other securities, of iCo from
time to time as circumstances warrant.
(f) the general nature and the material terms of any agreement, other than
lending arrangements, with respect to securities of the reporting issuer
entered into by the eligible institutional investor, or any joint actor, and
the issuer of the securities or any other entity in connection with any
transaction or occurrence resulting in the change in ownership or control
giving rise to the report, including agreements with respect to the
acquisition, holding, disposition or voting of any securities:
Not applicable.
(g) the names of any joint actors in connection with the disclosure required
hereunder:
AWM and the Funds may be considered to act jointly or in concert.
(h) Description of any change in any material fact set out in a previous report
by the eligible institutional investor under the early warning requirements
or Part 4 in respect of the reporting issuer’s securities:
Not applicable.
5610068 v1
- 3 -
(i) Statement of Eligibility
AWM is eligible to file reports under Part 4 of NI 62-103 in respect of iCo.
DATED this __30th___ day of _____January___________, 2014.
AWM Investment Company, Inc.
By:
/s/ David M. Greenhouse
David M. Greenhouse
Title: Executive Vice President of AWM
They attended and its behind us. Now let's see the impact over the next few weeks.
I suggest that you call the Company or IR if you want to confirm attendance.
Call the CFO - John Meekinson at the below details:
http://www.icotherapeutics.com/investor_relations/
IR - Hamza Thindal Capital Corp
Suite 1895 - 1066 West Hastings Street
Vancouver, BC V6E 3X1 CANADA
p: +1 604-566-9233
tf:+888.371.9098
f: +1 604-566-9232
e: info@htcapitalcorp.com
Hi Biocqr,
JPM Healthcare does not list attendees rather they show those presenting.
The volume that we are trading on the US side is quite telling that we are getting traction and this is just the beginning IMHO.
MMN
reetings everyone,
Below is a nice update from iCo Therapeutics Investor Relations.
What is great is that iCo will be presenting at the JP Morgan Healthcare Conference and I believe with their US listing (ICOTF) along with results being only 2 to 3 months away, this could be another great attention event.
On Friday the stock traded 1.1 million shares of which 448k+ were from the US and we broke the 50 cent mental barrier closing up 17%. Technically we have no major resistance till early 70's. Of course, this will not happen over night, but the way we are trading can tell that we will be heading there in the coming short while.
Good luck with your investment,
MMN
Subject: The Biotech Bull continues...
Date: Fri, 10 Jan 2014 09:43:35 -0800
The US Health Care and Biotech Market is continuing its tear with Intercept (NASDAQ: ICPT) announcing yesterday that they are stopping their Phase II trial early because the trial showed overwhelming efficacy data based on an interim analysis of the primary end point. The 283 patient, US based, multicenter Phase II trial is evaluating a treatment for non-alcoholic steatohepatitis (liver inflammation / fatty liver). The stock is up 370% since the announcement yesterday.
Our investment, ICO Therapeutics (TSX-V: ICO, OTCQX: ICOTF) will be reporting Phase II efficacy data from their own +180 patient, US based, multicenter Phase II trial for the treatment of Diabetic Macular Edema sometime in March/April 2014. The company recently listed on the OTCQ-X and has spent much of the past few years marketing the story in the US. We are seeing an inflow of interest already from the US and expect it to continue as the company gets set to report the single largest milestone in its history.
Next week the company will be attending the JP Morgan Healthcare Conference in San Francisco - Always a hotbed of investment and partnership activity.
--
Thanks and Best Regards,
Kyle Boyko
We are starting the year with great traction from the US side and I think this is just the start of things.
We traded 550k yesterday, more than 50% is US. As I am writing, we traded 408k and again 230k+ are US buying. This the first time iCo trades such volumes on the US front and goes to show how undervalued iCo is to its US peers. Buyers started adding as ICo started trading under ICOTF (QX listing) just 2 weeks ago.
We should have a nice run towards primary data, which come in March or April.
MMN
I think the filing made recently by Stuart Subotnick, who has filed a 13D in Digital Development Group (DIDG):
http://archive.fast-edgar.com/20131219/ADAOT22C8Z2262Z222ZP2MZZ6R65Z2T2D25Q/
He now owns over 10 Million shares of this small company!!
For more information on this substantial businessman see his Wiki here:
http://en.wikipedia.org/wiki/Stuart_Subotnick
From what I've found, Stu was the right hand man of John Kluge for many years. John, prior to Bill Gates and Warren Buffett was once the wealthiest man in America:
http://www.readthehook.com/66663/john-kluge-benevolent-billionaire-goes-out-style
Furthermore, Stuart/John's Media empire was partially sold to Rupert Murdoch as the genesis of what is now FOX Network. In short, these guys are players and as big as they come. What the heck is he doing investing in DIDG?!? Well, I think we'll find out more soon. But, honestly....how many times have you seen something like this occur/come true in a tiny penny stock?!?
The likelihood that this story is over is zero. It is just beginning and I am confident we will see aggressive awareness initiatives and press all over the place on this over the coming weeks. Plus, it bodes the question, what are they going to build here? This stock has been a disaster for the last 2 years but my due diligence led me to what I felt was a solid speculation that a lot of good things were in the pipeline. I don't know what the stock will do tomorrow but I'd guess it will be up nicely. Who knows...the stock may explode higher tomorrow/Monday.
The company also just launched a new website and I encourage everyone to take a look here: http://digidev.tv/
As always, please let me know if you have any questions, I look forward to hearing from you.